Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban versus enoxaparin after arthroscopic knee surgery
ChiCTR1800017265Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2018
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of rivaroxaban and enoxaparin in venous thromboembolism (VTE) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Incidence of venous thromboembolism, Mortality and 3 more. Planned start Aug 2018; status: not yet recruiting.
02
Drugs
rivaroxabanenoxaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on ChiCTR1800017265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017265.